Taiho Oncology, Inc.
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Taiho Oncology, Inc. is a clinical trial sponsor. It has 13 active clinical trials with 2,240 planned participants, across 11 therapeutic areas. Since 2021 it has completed 28 trials and stopped 22 early.
Trial track record · since 2021
Pipeline · 13 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
3 approved drug applications with a product on the market.
Questions about Taiho Oncology, Inc
Taiho Oncology, Inc is lead sponsor of 13 active clinical trials on ClinicalTrials.gov, with 2,240 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 28 trials and stopped 22 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Taiho Oncology, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Approve Suite is not affiliated with Taiho Oncology, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.